{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065482","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.808826+00:00","generated_at":"2026-06-07T22:35:24.420091+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sutro Biopharma promotes Jane Chung to President and COO effective Dec 1, 2023","bullets":["Jane Chung, previously Chief Commercial Officer, appointed President and COO, a newly created role.","New compensation includes $560k base salary, up to 50% bonus, 35k stock options, and 100k RSUs.","Chung previously served as President/GM of AstraZeneca Canada and VP of Immuno-Oncology at AstraZeneca.","Role focuses on operational excellence, strategic growth, and cross-functional alignment across R&D and portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065482","json":"https://secwatch.observer/filing/0000950170-23-065482.json","markdown":"https://secwatch.observer/filing/0000950170-23-065482.md","text":"https://secwatch.observer/filing/0000950170-23-065482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/stro-20231121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:35:24.420091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa398b052d","claim":"Jane Chung was appointed as President and Chief Operating Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On November 21, 2023, Sutro Biopharma, Inc. (the “Company”) announced the appointment of Jane Chung, currently the Company’s Chief Commercial Officer since August 2021, to the position of President and Chief Operating Officer of the Company, effective as of December 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}